IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Paul M. Ridker(Brigham and Women's Hospital), Matt Devalaraja, Florian M.M. Baeres(Novo Nordisk (Denmark)), Mads D.M. Engelmann(Novo Nordisk (Denmark)), G. Kees Hovingh(Novo Nordisk (Denmark)), Milana Ivkovic(Novo Nordisk (Denmark)), Larry Lo, Douglas Kling, Pablo E. Pérgola(Renal Associates P. A.), Dominic S. Raj(George Washington University), Peter Libby(Harvard University), Michael Davidson
The Lancet
May 1, 2021
Cited by 652

Abstract


Related Papers

No related papers found

Powered by citation graph analysis